Literature DB >> 23306195

Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy.

Kanishk Kapilashrami1, Gopal R Bommineni, Carl A Machutta, Pilho Kim, Cheng-Tsung Lai, Carlos Simmerling, Francis Picart, Peter J Tonge.   

Abstract

Thiolactomycin (TLM) is a natural product inhibitor of KasA, the β-ketoacyl synthase A from Mycobacterium tuberculosis. To improve the affinity of TLM for KasA, a series of TLM analogs have been synthesized based on interligand NOEs between TLM and a pantetheine analog when both are bound simultaneously to the enzyme. Kinetic binding data reveal that position 3 of the thiolactone ring is a suitable position for elaboration of the TLM scaffold, and the structure-activity relationship studies provide information on the molecular features that govern time-dependent inhibition in this enzyme system. These experiments also exemplify the utility of transient one-dimensional NOE spectroscopy for obtaining interligand NOEs compared with traditional steady state two-dimensional NOESY spectroscopy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306195      PMCID: PMC3585043          DOI: 10.1074/jbc.M112.414516

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Biochemical mechanisms of drug action: what does it take for success?

Authors:  David C Swinney
Journal:  Nat Rev Drug Discov       Date:  2004-09       Impact factor: 84.694

2.  Docking validation resources: protein family and ligand flexibility experiments.

Authors:  Sudipto Mukherjee; Trent E Balius; Robert C Rizzo
Journal:  J Chem Inf Model       Date:  2010-10-29       Impact factor: 4.956

3.  A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasites.

Authors:  Christina Spry; Christina L L Chai; Kiaran Kirk; Kevin J Saliba
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Cerulenin.

Authors:  S Omura
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.

Authors:  A C Price; K H Choi; R J Heath; Z Li; S W White; C O Rock
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

6.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Authors:  Jun Wang; Stephen M Soisson; Katherine Young; Wesley Shoop; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Gopalakrishnan Parthasarathy; Yui S Tang; Richard Cummings; Sookhee Ha; Karen Dorso; Mary Motyl; Hiranthi Jayasuriya; John Ondeyka; Kithsiri Herath; Chaowei Zhang; Lorraine Hernandez; John Allocco; Angela Basilio; José R Tormo; Olga Genilloud; Francisca Vicente; Fernando Pelaez; Lawrence Colwell; Sang Ho Lee; Bruce Michael; Thomas Felcetto; Charles Gill; Lynn L Silver; Jeffery D Hermes; Ken Bartizal; John Barrett; Dennis Schmatz; Joseph W Becker; Doris Cully; Sheo B Singh
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

7.  Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.

Authors:  Carl A Machutta; Gopal R Bommineni; Sylvia R Luckner; Kanishk Kapilashrami; Bela Ruzsicska; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

8.  Thiolactomycin, a new antibiotic. IV. Biological properties and chemotherapeutic activity in mice.

Authors:  S Miyakawa; K Suzuki; T Noto; Y Harada; H Okazaki
Journal:  J Antibiot (Tokyo)       Date:  1982-04       Impact factor: 2.649

9.  Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents.

Authors:  Patricia J Lee; Jayendra B Bhonsle; Heather W Gaona; Donald P Huddler; Tiffany N Heady; Mara Kreishman-Deitrick; Apurba Bhattacharjee; William F McCalmont; Lucia Gerena; Miriam Lopez-Sanchez; Norma E Roncal; Thomas H Hudson; Jacob D Johnson; Sean T Prigge; Norman C Waters
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

10.  Novel inhibitors of the condensing enzymes of the type II fatty acid synthase of pea (Pisum sativum).

Authors:  A L Jones; D Herbert; A J Rutter; J E Dancer; J L Harwood
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

View more
  10 in total

1.  Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.

Authors:  Gopal R Bommineni; Kanishk Kapilashrami; Jason E Cummings; Yang Lu; Susan E Knudson; Chendi Gu; Stephen G Walker; Richard A Slayden; Peter J Tonge
Journal:  J Med Chem       Date:  2016-05-24       Impact factor: 7.446

2.  Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.

Authors:  Johannes Schiebel; Kanishk Kapilashrami; Agnes Fekete; Gopal R Bommineni; Christin M Schaefer; Martin J Mueller; Peter J Tonge; Caroline Kisker
Journal:  J Biol Chem       Date:  2013-10-09       Impact factor: 5.157

Review 3.  Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.

Authors:  Mary Jackson; Michael R McNeil; Patrick J Brennan
Journal:  Future Microbiol       Date:  2013-07       Impact factor: 3.165

4.  A Structural Basis for Biguanide Activity.

Authors:  Scott A Gabel; Michael R Duff; Lars C Pedersen; Eugene F DeRose; Juno M Krahn; Elizabeth E Howell; Robert E London
Journal:  Biochemistry       Date:  2017-08-29       Impact factor: 3.162

Review 5.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents.

Authors:  Asma A Sager; Zainab S Abood; Wedad M El-Amary; Salah M Bensaber; Inass A Al-Sadawe; Nouri B Ermeli; Salah B Mohamed; Mohamed Al-Forgany; Ibrahim A Mrema; Mabrouk Erhuma; Anton Hermann; Abdul M Gbaj
Journal:  Open Med Chem J       Date:  2018-04-30

7.  Investigation of the anti-TB potential of selected propolis constituents using a molecular docking approach.

Authors:  Mohammad Tuhin Ali; Natalia Blicharska; Jamil A Shilpi; Veronique Seidel
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

8.  Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.

Authors:  Pradeep Kumar; Glenn C Capodagli; Divya Awasthi; Matthew B Neiditch; Joel S Freundlich; David Alland; Riju Shrestha; Karishma Maharaja; Paridhi Sukheja; Shao-Gang Li; Daigo Inoyama; Matthew Zimmerman; Hsin Pin Ho Liang; Jansy Sarathy; Marizel Mina; George Rasic; Riccardo Russo; Alexander L Perryman; Todd Richmann; Aditi Gupta; Eric Singleton; Sheetal Verma; Seema Husain; Patricia Soteropoulos; Zhe Wang; Roxanne Morris; Gene Porter; Gautam Agnihotri; Padmini Salgame; Sean Ekins; Kyu Y Rhee; Nancy Connell; Véronique Dartois
Journal:  mBio       Date:  2018-12-18       Impact factor: 7.867

9.  Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products.

Authors:  Rafael Baptista; Sumana Bhowmick; Jianying Shen; Luis A J Mur
Journal:  Molecules       Date:  2021-01-18       Impact factor: 4.411

Review 10.  Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design.

Authors:  Reshma S Rudraraju; Samer S Daher; Ricardo Gallardo-Macias; Xin Wang; Matthew B Neiditch; Joel S Freundlich
Journal:  Front Cell Infect Microbiol       Date:  2022-09-15       Impact factor: 6.073

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.